Emoha is an elder care startup based in Gurugram, India, that provides home-based care and emergency support for senior citizens; it is part of Age Care Labs.
This Startup Deep Dive explains what Emoha does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.
Emoha in Brief
- What it is: Emoha is an Indian Home-based elder care company based in Gurugram.
- Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
- Emoha offers home-based services including geriatric care, emergency assistance, health monitoring, hospital accompaniment and social engagement.
- Emoha sits under Age Care Labs, which also owns Epoch Elder Care.
- October 2023: parent Age Care Labs raised $11 million in a pre-Series B round with Rainmatter Capital, Gruhas and Lumis Labs (reported).
- Funding: Over $20 million raised by parent Age Care Labs (reported).
Emoha Quick Facts
| Company | Emoha |
| Founded | Not disclosed |
| Headquarters | Gurugram |
| Founders | Saumyajit Roy |
| Sector | Home-based elder care |
| Total funding | Over $20 million raised by parent Age Care Labs (reported) |
| Latest round | Rs 85 crore (about $9 million) Series B1 by parent Age Care Labs, July 2026 (reported) |
| Valuation | Not disclosed |
| Website | Not disclosed |
Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.
What Is Emoha?
Emoha operates in the Home-based elder care space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Emoha.
- Emoha offers home-based services including geriatric care, emergency assistance, health monitoring, hospital accompaniment and social engagement.
- Emoha sits under Age Care Labs, which also owns Epoch Elder Care.
The Origin Story of Emoha
Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.
- Founders: Saumyajit Roy.
- Age Care Labs is described as anchored by Lumis Partners in 2019 with Saumyajit Roy; Roy is co-founder and CEO of Emoha.
Key Milestones and Challenges
No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Home-based elder care sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.
- October 2023: parent Age Care Labs raised $11 million in a pre-Series B round with Rainmatter Capital, Gruhas and Lumis Labs (reported).
- July 2026: Age Care Labs raised Rs 85 crore in a Series B1 round and formed Shremoha with Shrem Group, a premium senior independent living platform (reported).
Emoha Funding and Investors
Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.
- October 2023: $11 million pre-Series B at Age Care Labs level (reported).
- July 2026: Rs 85 crore (about $9 million) Series B1 at Age Care Labs level; sources differ on whether Shrem led or participated, with Rainmatter and Pegasus Finvest also in (reported).
- Age Care Labs has raised over $20 million to date from investors including Lumis Partners, Rainmatter, Gruhas and KOIS Invest (reported).
How Does Emoha Make Money? (Business Model)
A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.
- Revenue sources: The exact revenue mix of Emoha is not disclosed in public sources reviewed.
- What to look for: Recurring contracts, repeat customers, gross margin trend and payback on customer acquisition.
The Numbers: Emoha Financials
Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.
- FY25: revenue from operations Rs 74.35 crore, up 40% from Rs 53.21 crore in FY24; loss Rs 36.68 crore versus Rs 54.16 crore in FY24 (provisional, reported before official filing).
- FY24: another source gives revenue of Rs 53.68 crore and a loss of Rs 54.16 crore versus Rs 32.66 crore in FY23 (reports differ slightly on FY24 revenue).
Market Opportunity for Emoha
Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.
- Demand drivers: rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings.
- Reach: How much of the market Emoha can serve depends on its product readiness, distribution and regulatory approvals.
Technology and Product at Emoha
Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.
- Core capability: Public detail on Emoha’s technology stack is limited beyond company-stated descriptions.
- Assessment lens: clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.
Team and Culture at Emoha
Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.
- Saumyajit Roy is co-founder and CEO of Emoha.
Emoha Competitors: Competitive Landscape
A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.
| Competitor | How it differs |
|---|---|
| Samarth Elder Care | Elder care services startup that appeared alongside Emoha in elder care coverage. |
Risks and Challenges for Emoha
- Emoha still reports large losses (Rs 36.68 crore in FY25, provisional) despite a 32% reduction.
- Fundraising sits at the Age Care Labs level, and a larger Rs 250 crore Series B is only planned for the first quarter of 2027.
- Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
- Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
- Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.
Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.
Emoha Growth Outlook: What to Watch
- Age Care Labs plans a larger Series B of Rs 250 crore (about $30 million), expected to launch in the first quarter of 2027.
- Funds are meant to expand services, invest in technology and strengthen healthcare capabilities across India; Shremoha will develop senior living communities.
- Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
- Funding position: Whether Emoha can reach its next milestone before needing new capital.
- Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.
Industry Context: Where Emoha Fits
India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.
Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.
For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.
Bull Case and Bear Case for Emoha
An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Emoha.
Bull case
- Rising insurance cover and digital adoption expand the customer base.
- Strong clinical evidence builds trust with doctors and hospitals.
- Scale can improve unit economics in diagnostics and care delivery.
Bear case
- Regulatory changes can alter permitted products or business models.
- Customer acquisition costs can erode margins.
- A single safety or privacy incident can damage trust.
Lessons Founders and Investors Can Take from Emoha
Studying a company in the Home-based elder care space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Emoha.
- Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
- Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
- Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
- Regulatory approvals can take time, so timelines and cash planning should allow for them.
- Integration with existing hospital, lab and records systems reduces friction for adoption.
How to Evaluate Emoha as a Startup
- Customer clarity: Can Emoha name its customer and the problem it solves in one sentence?
- Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
- Economics: Check whether margins improve as volume grows.
- Execution: Compare announced timelines with what has actually been delivered.
- Funding runway: Estimate how long current capital lasts at the present spending rate.
- Regulatory standing: Confirm required approvals are in place.
- Customer concentration: Check whether a few customers account for most of the revenue.
- Management depth: Look for experienced leaders beyond the founders and a stable core team.
The Takeaway
Emoha is part of India’s growing Home-based elder care ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. This article is educational and is not investment advice.
- Clear customers and repeat demand matter more than announcements.
- Regulation and capital needs shape how fast a startup in this sector can grow.
- Track a few leading indicators over time rather than one headline metric.
Emoha FAQs: Frequently Asked Questions
What is Emoha?
Emoha is an elder care startup based in Gurugram, India, that provides home-based care and emergency support for senior citizens; it is part of Age Care Labs. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.
Who founded Emoha?
Emoha was founded by Saumyajit Roy.
How much funding has Emoha raised?
Over $20 million raised by parent Age Care Labs (reported). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.
How does Emoha make money?
Emoha earns revenue from its Home-based elder care products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.
Who are the competitors of Emoha?
Reported rivals include Samarth Elder Care. See the competitor comparison above for how they differ.
What are the main risks for Emoha?
Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.
Related Startup Deep Dives: Docplexus — Docplexus: Pune doctors’ network backed by $700K seed | Piersight Space — Ahmedabad startup building a SAR ocean-watching constellation. Browse the full Startup Deep Dive series.
Source
Source: Publicly available data, published reports, industry research, and other credible sources.




